Loading clinical trials...
Loading clinical trials...
Prediction of Cardiotoxicity Using Serum N-terminal Pro-B-type Natriuretic Peptide in Breast Cancer Patients Receiving Adjuvant Trastuzumab
Conditions
Locations
15
Australia
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia
Royal North Shore Private Hospital
Sydney, New South Wales, Australia
Sydney Haematology Oncology Clinic
Sydney, New South Wales, Australia
Concord Hospital
Sydney, New South Wales, Australia
Liverpool Hospital
Sydney, New South Wales, Australia
Bankstown Hospital
Sydney, New South Wales, Australia
Start Date
February 1, 2009
Primary Completion Date
July 1, 2013
Completion Date
June 1, 2014
Last Updated
November 5, 2014
NCT07484009
NCT07191730
NCT04419480
NCT07105007
NCT06797635
NCT06312176
Lead Sponsor
Royal Prince Alfred Hospital, Sydney, Australia
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions